Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

Final Appraisal Recommendation

Advice No: 0221 – February 2021

Dupilumab (Dupixent®) 200 mg and 300 mg solution for injection in pre-filled syringe, 200 mg and 300 mg solution for injection in pre-filled pen

Limited submission by Sanofi-Aventis

Recommendation of AWMSG

Dupilumab (Dupixent®) is recommended as an option for restricted use within NHS Wales.

Dupilumab (Dupixent®) is licensed for the treatment of severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy.

Dupilumab (Dupixent®) is restricted for the treatment of severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy and where existing systemic therapies are not advisable.

Dupilumab (Dupixent®) is not recommended for use within NHS Wales outside of this subpopulation.

This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.

Additional note:

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3858), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.